Long standing and poorly managed warfarin intake is highly associated with complications like major bleeding that is difficult to control in case of severe hemorrhage. However, the recent FDA Approval of Kcentra after Pivotal Clinical Trial under Dr. Ravi Sarode suggests that the intake of PCC can lead to the reversal of acquired coagulation factor deficiency in warfarin treated individuals.
http://bionews-tx.com/news/2013/05/01/fda-approves-pcc-to-reverse-warfarin-induced-acute-bleeding/
No comments:
Post a Comment